Last update Feb. 5, 2022
Volatile sympathomimetic with vasoconstrictor effect used as a nasal decongestant. It has hypertensive and tachycardial effects(Marsh 1951). Administration by intranasal spray.
At the date of the last update, there was no published data available on its excretion in human milk.
Product with very few and very old bibliographic references, marketed in few countries.
The virtual absence of pharmacokinetic data does not allow the prediction of its possible excretion in human milk.
Tuaminoheptane has been on the list of prohibited substances by the World Anti-Doping Agency since 2007. (Docherty 2008, Thevis 2007)
Urine levels are detected up to 2 to 4 days after intranasal administration. (Perrenoud 2009, Thevis 2007).
The isolated application, occasional, not continuous and without exceeding the prescribed dose could be compatible with breastfeeding.
Until more published data are known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM